Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;1(2):102-106.
doi: 10.15420/cfr.2015.1.2.102.

Role of Cardiac Troponin Levels in Acute Heart Failure

Nicholas Wettersten  1 , Alan Maisel  2
Affiliations

Role of Cardiac Troponin Levels in Acute Heart Failure

Nicholas Wettersten et al. Card Fail Rev. 2015 Oct.

Abstract

Cardiac troponin (cTn) is the primary biomarker for the diagnosis of myocardial necrosis in an acute coronary syndrome (ACS). cTn levels can also be elevated in many other conditions, including heart failure, with significant prognostic value. An elevated cTn level can be found in both acute and chronic heart failure and its presence is believed to be due to multiple different pathophysiological processes. In acute decompensated heart failure (AHF), an elevated cTn level has been repeatedly shown to correlate with increased short- and long-term mortality and, to a lesser extent, readmission rates. These associations have been demonstrated with both I and T isoforms of cTn, as well as when troponin is measured with conventional assays or new high-sense assays. In multimarker models, cTn has repeatedly been found to be an independent predictive variable enhancing prognostic ability of the model. cTn is therefore an important biomarker for prognosis in AHF.

Keywords: Acute decompensated heart failure; biomarkers; mortality; readmission; risk prediction; troponin.

PubMed Disclaimer

Conflict of interest statement

Disclosure: N Wettersten has no conflicts of interest to declare. A Maisel has received grant support from Roche Diagnostics, Alere and Abbott.

Figures

Figure 1:
Figure 1:. Different Pathophysiologic Processes that Can Lead to Elevated Troponin Levels
Figure 2:
Figure 2:. Total Number of Patients With and Without Positive Troponin Test Results
Figure 3:
Figure 3:. 90-day Event-free (Death or Readmission) Curves for P atients Based on Discharge hsTnI
See this image and copyright information in PMC

References

    1. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–1598. - PubMed
    1. Maisel A. Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol. 2011;58:1890–1892. - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147–239. - PubMed
    1. Perna ER, Cimbaro Canella JP, Macin SM. Importance of myocardial damage in acute decompensated heart failure: changing the paradigm from a passive to an active process. Minerva Cardioangiol. 2005;53:523–535. - PubMed
    1. Kociol RD, Pang PS, Gheorghiade M, et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071–1078. - PubMed